Results 31 to 40 of about 2,875 (114)

Recognising Mild Cognitive Impairment and Early Alzheimer's Disease in General and Psychiatric Practice: Clinical Clues and Appropriate Referral

Psychogeriatrics, Volume 26, Issue 6, November 2026.
ABSTRACT Early cognitive decline may become evident through changes in daily activities or behaviour before it is apparent in a brief consultation. This selective narrative review supports case‐finding and appropriate referral in general and psychiatric practice.
Kengo Shimoda
wiley   +1 more source

Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial

Neurology and Therapy
Introduction Donanemab, a monoclonal antibody directed against an insoluble, modified, N-terminal truncated form of amyloid beta, demonstrated efficacy and safety in patients with early, symptomatic Alzheimer’s disease (AD) in the phase 3 TRAILBLAZER-ALZ
Shoichiro Sato, Naohisa Hatakeyama, Shinji Fujikoshi, Sadao Katayama, Hideaki Katagiri, John R. Sims   +5 more
doaj   +1 more source

Infusion‐related reactions in donanemab‐treated participants with early symptomatic Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Infusion‐related reactions (IRRs) and hypersensitivity are adverse events associated with therapeutic antibodies. Characterization of IRRs can lead to improved risk anticipation and management of this event.
Paul Ardayfio, Garrett R. Mullins, Rashna Khanna, Jennifer A. Zimmer, Hong Wang, Emel Serap Monkul Nery, Cynthia D. Evans, Pawel Piela, Chakib Battioui, Steve Lauzon, Greg Anglin, Hui Wen Ng, Anu Rita Jayaraman, Noah Agada, Chitra R. Natalie, Dawn A. Brooks, John R. Sims   +16 more
doaj   +1 more source

Perspectives from Alzheimer's Disease Research Centers site directors on the early steps and the lasting impact

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract Since the groundbreaking work of Alois Alzheimer in the early 1900s, Alzheimer's disease research has evolved immensely, most notably with the establishment of the Alzheimer's Disease Research Centers (ADRC). Fueled by the vision and funding of the National Institute on Aging (NIA), ADRCs have created a legacy through their work standardizing ...
John H. Growdon, John C. Morris, Ronald C. Petersen, Mary Sano, Lon S. Schneider   +4 more
wiley   +1 more source

Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model.

PLoS Computational Biology, 2022
With the recent approval by the FDA of the first disease-modifying drug for Alzheimer's Disease (AD), personalized medicine will be increasingly important for appropriate management and counseling of patients with AD and those at risk.
Wenrui Hao, Suzanne Lenhart, Jeffrey R Petrella   +2 more
doaj   +1 more source

Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Anti‐amyloid antibody clinical trials with a high proportion of participants reaching treatment‐related amyloid clearance (TRAC) had positive clinical outcomes. We evaluated the aducanumab phase 3 program to determine whether TRAC during the double‐blind period was likewise associated with clinical benefit.
Menglan Pang, Holly M. Brothers, John O'Gorman, Jennifer Murphy, Yuval Zabar, Tyler Lasky, Changyu Shen, Ivana Rubino, David Knopman   +8 more
wiley   +1 more source

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve

Biomedicines
Background: Monoclonal antibodies approved by the FDA, lecanemab, donanemab, and aducanumab, are failing to meet the expected efficacy to treat early Alzheimer’s disease, and aducanumab has been recalled.
Sarfaraz K. Niazi
doaj   +1 more source

Genetic evidence supports a cortical neuroprotective role of GLP‐1 receptor activation in Alzheimer's disease: A drug‐target Mendelian randomization study

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Whether glucagon‐like peptide‐1 (GLP‐1) receptor (GLP‐1R) activation lowers Alzheimer's disease (AD) risk via peripheral metabolic improvement or direct neuroprotection remains unclear. METHODS Using blood and brain‐cortex cis‐acting expression quantitative trait loci (cis‐eQTLs) for GLP‐1R as instruments, we performed cis ...
Li Jiang, Xinyuan Chen, Jiangshun Qian, Kaiwen Fang, Chenyuan Dai, Dong Chang, Liang Jin, Wenjin Huang, Yuzheng Wang, Xiaomei Duan, Juan Wan, Mingqiang Li, Wendiao Zhang, Jinchen Li, Zijian Xiao, Heng Wu, Qingtuan Meng, Beisha Tang   +17 more
wiley   +1 more source

Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY‐AD and TRAILBLAZER‐ALZ2

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION This study investigated evidence for or against a difference in treatment effect between women and men for lecanemab and donanemab. METHODS Data were derived from supplementary analyses of the regulatory studies CLARITY‐AD (lecanemab) and ...
Stefan J. Teipel, Yi Tang, Ara Khachaturian   +2 more
doaj   +1 more source

Caregiver positivity as a psychosocial modifier of lecanemab‐related outcomes in Alzheimer's disease: A multicenter longitudinal study in China

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Real‐world modifiers of lecanemab benefit in Alzheimer's disease (AD) remain elusive. We examined associations between caregiver positivity and longitudinal outcomes in AD. METHODS This seven‐center longitudinal study followed 127 biomarker‐supported AD patient–caregiver dyads over 18 months.
Wenjing Wu, Huayan Liu, Yun Liang, Huai'an Li, Jinhong Zhang, Zhen Sun, Yehua Song, Min Fei, Hao Wu, Mo Jiang, Shiyv Fan, Chaohui Zhou, Yv Cao, Hui Chen, Shuai Liu   +14 more
wiley   +1 more source